CHM Chimeric Therapeutics Limited
—Mkt Cap: —P/E: —1d ago
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the tr…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value17.45K USD
Revenue (TTM)-131.20K USD
Gross Profit2.16M USD
Net Income (TTM)-7.21M USD
Revenue/Share-0.0060 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000121576
Valuation
P/E (Trailing)—
P/E (Forward)-0.05
PEG—
EV/EBITDA-0.00
EV/Revenue-0.13
P/S-2.33
P/B-0.02
EPS (TTM)-0.61
EPS (Forward)-0.06
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin78.66%
Oper. Margin258.99%
EBITDA Margin0.00%
Profit Margin-262.83%
ROE-528.25%
ROA-48.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.45M USD
CapEx (TTM)—
FCF Margin3558.76%
FCF Yield—
Net Debt-96.01K USD
Net Debt/EBITDA0.02
Balance Sheet
Debt/Equity—
Current Ratio0.12
Quick Ratio0.09
Book Value/Sh-0.14 AUD
Cash/Share0.01 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateApr 22, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.147.46M
Float44.95M
Insiders15.01%
Institutions1.18%
Technical
SMA 500.0122 AUD
SMA 2000.1119 AUD
Beta0.88
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)0
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—